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Abstract
Introduction: Reports of secondary diabetes in glycogen storage disease type III have been very
limited, where the pathogenesis and management have not been clear. Here we report on a rare case
of secondary diabetes in glycogen storage disease type III that has been successfully managed with
insulin.
Case presentation: This is a 19-year-old female of Egyptian ethnicity, born of a consanguineous
marriage and known to have glycogen storage disease type III since the age of 2½ years. She
presented to us with a history of polyuria, polydipsia, and loss of weight of a few days duration.
Physical exam showed stunted growth, hepatomegaly, myopathy and mild dehydration. Emergency
labs revealed a fasting blood glucose of 276 mg/dl, but with no ketonuria and arterial blood gases
were essentially normal. Her liver transaminases were mildly elevated at the time. Review of her
records revealed that the diagnosis of glycogen storage disease type III was made at the age of 2½
when the mother reported repeated attacks of afebrile (hypoglycemic) convulsions, increasing
abdominal girth and failure to thrive. The diagnosis was confirmed by demonstration of debrancher
enzyme deficiency on enzymatic assay. Over the years she developed liver dysfunction along with
other complications and subsequently her hypoglycemic attacks disappeared a few years prior to her
current presentation. After careful consideration of different treatment options, and considering she
had been free of hypoglycemic attacks for a few years and had liver dysfunction, we chose to
cautiously initiate the patient on insulin therapy. She was still poorly controlled and we gradually
increased her total daily dose to 0.8 u/kg. She continued to be free of hypoglycemic attacks and her
average daily blood glucose is about 160 mg/dl.
Conclusion: We report a rare case of secondary diabetes mellitus in a patient with glycogen storage
disease type III managed with insulin. We recommend insulin therapy over oral hypoglycemics to
avoid further hepatotoxicity, provided hypoglycemia has resolved. We also recommend serial follow
up of glycogen storage disease type III patients with an oral glucose tolerance test for early detection
and management of glucose intolerance.
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Glycogen-storage disease type III (GSD III) is an auto-
somal recessive metabolic disorder caused by loss of
function mutations of the glycogen debranching enzyme
(Amylo-1,6-glucosidase) gene, located at chromosome
band 1p21.2. It is characterized by the storage of abnormal
glycogen in both skeletal and cardiac muscle and/or the
liver, with variability in resultant organ dysfunction. Major
manifestations of GSDIII include hypoglycemia (which
may improve and disappear with age), hepatomegaly with
elevated transaminases, hyperlipidemia, hyperuricemia,
and skeletal myopathy/cardiomyopathy with increased
creatine phosphokinase (CPK). There is no specific
treatment for GSDs, but diet therapy with nocturnal
nasogastric tube feeding and cornstarch improves symp-
toms (especially hypoglycemia), reduces the liver size, and
improves overall growth and development [1]. Rare
complications of GSDIII include liver cirrhosis and failure
together with secondary glucose intolerance and frank
diabetes. However, reports of such cases have been very
few. Diabetes mellitus (DM) in GSD III is difficult to treat
because patients are prone to hypoglycemia. We, however,
report on a case of GSDIII with secondary diabetes
successfully controlled with insulin.
Case presentation
This is a19-year-old femaleof Egyptian ethnicity, born of a
consanguineous marriage and known to have glycogen
storage disease type III since the age of 2½ years. She
presented to us with a history of several days of polyuria,
polydipsia, and loss of weight.
Review of her records revealed that she had been
diagnosed with GSDIII at the age of 2½ years, when the
mother reported an increasing abdominal girth, failure to
thrive, and repeated attacks of afebrile convulsions of
1 year duration. The diagnosis of GSDIII was confirmed at
the time by a liver biopsy showing a picture suggestive of
GSD (swollen cells and mosaic cytoplasmic appearance
with mild fibrosis) as well as demonstration of debrancher
enzyme deficiency. She was prescribed long-term therapy
with cornstarch for hypoglycemia and colchicine for
associated hyperuricemia. Unfortunately, there was vari-
able follow-up by the mother together with non-adher-
ence to management regimens.
Over the years she developed progressive chronic liver
dysfunction with persistently high liver transaminases and
g-glutamyl transpeptidase together with coagulation pro-
file compromise and bleeding tendency. Jaundice was
documented only once during an attack of acute hepatitis
on top of her chronic dysfunction. Her most recent follow-
up liver biopsy (done years prior to her current presenta-
tion) had shown increased fibrosis and changes suggestive
of very early cirrhosis, but with intact limiting plates.
Subsequently, evidence of vitamin D and A deficiencies
developed with metastatic soft tissue calcifications and
osteoporotic bone fractures, together with poor night
vision and dry skin, respectively. Moreover, the patient
later developed myopathy, with progressive muscle weak-
ness and pain, indicating a diagnosis of GSDIII type a
(both liver and muscle involvement). Fortunately, about
four years prior to her current presentation the patient’s
hypoglycemic attacks improved and eventually disap-
peared. Her family history is positive for two younger sibs,
both diagnosed with GSD.
Upon physical exam, she appeared dysmorphic, stunted,
with a mild degree of dehydration and dry skin.
Abdominal exam revealed a firm and enlarged liver, but
with no splenomegaly or ascites. Neuromuscular system
examination revealed reduced muscle power in both
upper and lower limbs, while cardiovascular system
exam excluded any evidence of cardiomyopathy. Pubertal
staging revealed primary amenorrhea, but with adequate
development of secondary sex characters. Positive clinical
findings are summarized in Table 1.
Emergency labs done at the time of presentation revealed a
fasting blood glucose (FBG) of 276 mg/dl and no ketones.
Her arterial blood gases (ABG) were essentially normal
with a pH of 7.36, PCO2 44.1, HCO3 22.1, BE -1.1.
Further lab studies showed pus cells in urine, and a culture
later grew Escherichia coli. A complete blood count with a
differential count showed a marked shift to the left. Her
liver transaminases, g-glutamyl transpeptidase and alka-
line phosphatase were mildly elevated, while her kidney
functions and electrolytes were normal. Her uric acid and
lactate levels were also normal, but her creatine phospho-
kinase was high at the time.
After careful consideration of different treatment options
and considering the patient was free of hypoglycemic
attacks for an adequate time without treatment and that
she had already developed liver dysfunction and early
cirrhosis, we decided to begin the patient on very low
doses of insulin therapy. She continued to show high
blood glucose (BG) readings with a daily average of about
263 mg/dl, requiring that we gradually increase her total
Table 1. Clinical presentation of our case
Physical Examination Positive Findings
General appearance Facial dysmorphism and stunted growth
Anthropometry Height -2.2 SDS, Weight -4 SDS
Skin Dry skin and mild dehydration
Abdominal Liver ≈ 5 cm below the costal margin and firm
Neuromuscular Bilateral and symmetrically reduced muscle
power (4/5) in both upper and lower limbs
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controlled and has continued to be free of hypoglycemic
attacks; rather she tends to err on the high side with a daily
average BG of approximately 160 mg/dl. Figure 1 shows
average daily glucose levels during the initial period of
dose adjustment.
Discussion
Reports on the pathogenesis of secondary diabetes in
GSDIII and its management have been very limited and
relatively unclear [2,3]. Glucose intolerance and secondary
diabetes in GSDIII is thought to result from liver
dysfunction. The pathogenesis of glucose intolerance in
liver dysfunction in general also remains unclear, where
several factors are thought to be responsible, including
insulin resistance, insulin hypersecretion with reduced
clearance, impaired glycogen catabolism, defective adipo-
cyte insulin sensitivity and others. Diabetes development
in patients with liver cirrhosis, regardless of etiology,
shows that about 80% develop glucose intolerance, while
up to 40% can develop frank DM [4,5]. Early on there is
post-prandial hyperglycemia (PPHG), but later on there is
both fasting & PPHG. Of note here is that our patient had
already developed liver dysfunction and early cirrhosis at
the time she presented to us. She was unfortunately missed
during the earlier stages of intolerance and PPHG due to
her loss to follow up.
Classically, DM associated with liver cirrhosis is treated
with insulin; however, this becomes a major problem if
cirrhosis is secondary to GSDIII due to the high risk of
hypoglycemia. Oki et al. [3] described an adult GSDIII
patient who later developed liver dysfunction. This
dysfunction worsened over the years, and he subsequently
developed PPHG. Being that this patient presented
with PPHG, the authors chose to treat him with an
a-glucosidase inhibitor, voglibose. Alpha-glucosidase
inhibitors blunt PPHG by essentially delaying the hydro-
lysis of carbohydrates in the intestines. Accordingly, there
is a low risk for hypoglycemia. However, when this option
was considered in our patient, it was thought unhelpful
given that she had presented to us at a more advanced
stage of fasting hyperglycemia. Furthermore, there has
been conflicting evidence regarding the potential hepato-
toxicity of voglibose [6-8]. So considering our case had
elevated liver transaminases, we chose not to take this risk.
Due to the patient's presentation with fasting hyperglyce-
mia, the spontaneous resolution of her hypoglycemic
attacks for several years prior to clinical diabetes, and the
potential hepatotoxic effect of most oral hypoglycemics,
we decided to manage her diabetes with insulin therapy
and have been so far successful.
Conclusion
We report a rare case of secondary DM in a GSDIII patient
who has been successfully managed with insulin. We
recommend insulin therapy over oral hypoglycemics to
avoid further hepatotoxicity, provided hypoglycemias have
resolved. We also recommend serial follow up of GSDIII
patients with an oral glucose tolerance test (OGTT) for early
detection and management of glucose intolerance.
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Figure 1. Daily blood glucose levels on different insulin doses.
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